Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) FCF Margin (2016 - 2025)

Amicus Therapeutics filings provide 14 years of FCF Margin readings, the most recent being 10.35% for Q4 2025.

  • On a quarterly basis, FCF Margin rose 1316.0% to 10.35% in Q4 2025 year-over-year; TTM through Dec 2025 was 5.21%, a 1230.0% increase, with the full-year FY2025 number at 5.21%, up 1230.0% from a year prior.
  • FCF Margin hit 10.35% in Q4 2025 for Amicus Therapeutics, down from 19.42% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 19.42% in Q3 2025 to a low of 110.27% in Q1 2021.
  • Median FCF Margin over the past 5 years was 19.1% (2022), compared with a mean of 28.56%.
  • Biggest five-year swings in FCF Margin: soared 9623bps in 2023 and later crashed -3362bps in 2025.
  • Amicus Therapeutics' FCF Margin stood at 90.16% in 2021, then decreased by -5bps to 94.73% in 2022, then skyrocketed by 102bps to 1.5% in 2023, then plummeted by -287bps to 2.81% in 2024, then soared by 469bps to 10.35% in 2025.
  • The last three reported values for FCF Margin were 10.35% (Q4 2025), 19.42% (Q3 2025), and 17.12% (Q2 2025) per Business Quant data.